Failure of non-vitamin K antagonist oral anticoagulants in preventing stroke in elderly patient: a case report of multiple strokes on standard of care treatment for atrial fibrillation
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
http://orcid.org/0000-0002-7659-6029
Azam Mohiuddin
http://orcid.org/0000-0001-9147-5324
Abstract
Atrial fibrillation (AF) is the most common type of treated heart arrhythmia. Generally, the treatment goals for atrial fibrillation are to reset the rhythm or control the rate and prevent the development and subsequent embolization of atrial thrombi. These thromboembolic events can occur with any kind of atrial fibrillation that is paroxysmal, persistent or permanent. In patients who are candidate for anticoagulation therapy, major practice guideline provides vitamin K antagonist (VKA) oral anticoagulant and non-VKA oral anticoagulants as treatment options. The risk of AF increases with age and despite treatment on standard of care anticoagulation therapy, recrudescent cardioembolic events may still arise especially in the elderly as we will see in this case.
##plugins.themes.bootstrap3.article.details##
atrial fibrillation, oral anticoagulation, stroke
doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.019
2. Benjamin E, Wolf P, D'Agostino R, Silbershatz H, Kannel W, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham: Heart Study. Circulation 1998; 98(10):946–952.
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155(5):469–473. http://doi: 10.1001/archinte.1995.00430050045005 .
4. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: Systematic review and meta-analysis. Circulation 2015; 132(3):194-204.
http://doi:10.1161/CIRCULATIONAHA.114.013267.
5. Manno G, Novo G, Corrado E, Coppola G, Novo S. Use of direct oral anticoagulants in very elderly patients: A case report of apixaban in an ultracentenary patient. J Cardiovasc Med 2019; 20(6):403-405.
6. Scowcroft ACE, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: An analysis using the general practice research database (GPRD) 2000–2009. Heart 2013; 99(2):127-132. http://dx.doi.org/10.1136/heartjnl-2012-302843.
7. January CT, Wann LS, Alpert JS, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [erratum in Circulation 2014; 130(23):e270-271]. Circulation 2014; 130(23):2071-2104. http://doi:10.1161/CIR.0000000000000040.
8. Pengo V, Denas, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132(13):1365–1371. https://doi.org/10.1182/blood-2018-04-848333.
9. Wada S, Toyoda K, Sato S, et al. Anti-Xa activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke. Circ J 2018; 82(11):2872-2879.
http://doi:10.1253/circj.CJ-18-0506.
10. Godino C, Bodega F, Melillo F, et al. Investigators Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. J Cardiovasc Med 2020; 21(10):751-758.
http://doi:10.2459/JCM.0000000000001043
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.